12 results on '"Junking, Mutita"'
Search Results
2. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer
- Author
-
Somboonpatarakun, Chalermchai, Phanthaphol, Nattaporn, Suwanchiwasiri, Kwanpirom, Ramwarungkura, Boonyanuch, Yuti, Pornpimon, Poungvarin, Naravat, Thuwajit, Peti, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Published
- 2024
- Full Text
- View/download PDF
3. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1
- Author
-
Luangwattananun, Piriya, Sangsuwannukul, Thanich, Supimon, Kamonlapat, Thuwajit, Chanitra, Chieochansin, Thaweesak, Sa-nguanraksa, Doonyapat, Samarnthai, Norasate, O-Charoenrat, Pornchai, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Published
- 2023
- Full Text
- View/download PDF
4. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition
- Author
-
Yuti, Pornpimon, Wutti-in, Yupanun, Sawasdee, Nunghathai, Kongkhla, Katesara, Phanthaphol, Nattaporn, Choomee, Kornkan, Chieochansin, Thaweesak, Panya, Aussara, Junking, Mutita, Yenchitsomanus, Pa-thai, and Sujjitjoon, Jatuporn
- Published
- 2022
- Full Text
- View/download PDF
5. NF-κB is required for dengue virus NS5-induced RANTES expression
- Author
-
Khunchai, Sasiprapa, Junking, Mutita, Suttitheptumrong, Aroonroong, Kooptiwut, Suwattanee, Haegeman, Guy, Limjindaporn, Thawornchai, and Yenchitsomanus, Pa-thai
- Published
- 2015
- Full Text
- View/download PDF
6. Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers
- Author
-
Phumesin, Patta, Junking, Mutita, Panya, Aussara, Yongpitakwattana, Petlada, Noisakran, Sansanee, Limjindaporn, Thawornchai, and Yenchitsomanus, Pa-thai
- Published
- 2019
- Full Text
- View/download PDF
7. Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A.
- Author
-
Rattanaburee, Thidarath, Junking, Mutita, Panya, Aussara, Sawasdee, Nunghathai, Songprakhon, Pucharee, Suttitheptumrong, Aroonroong, Limjindaporn, Thawornchai, Haegeman, Guy, and Yenchitsomanus, Pa-thai
- Subjects
- *
DENGUE , *THERAPEUTICS , *DENGUE viruses , *RIBAVIRIN , *ANTI-inflammatory agents , *CYTOKINES , *ANTIVIRAL agents , *GENE expression - Abstract
Dengue virus (DENV) infection is a worldwide public health problem with an increasing magnitude. The severity of disease in the patients with DENV infection correlates with high viral load and massive cytokine production – the condition referred to as “cytokine storm”. Thus, concurrent inhibition of DENV and cytokine production should be more effective for treatment of DENV infection. In this study, we investigated the effects of the antiviral agent – ribavirin (RV), and the anti-inflammatory compound – compound A (CpdA), individually or in combination, on DENV production and cytokine/chemokine transcription in human lung epithelial carcinoma (A549) cells infected with DENV. Initially, the cells infected with DENV serotype 2 (DENV2) was studied. The results showed that treatment of DENV-infected cells with RV could significantly reduce both DENV production and cytokine (IL-6 and TNF-α) and chemokine (IP-10 and RANTES) transcription while treatment of DENV-infected cells with CpdA could significantly reduce cytokine (IL-6 and TNF-α) and chemokine (RANTES) transcription. Combined RV and CpdA treatment of the infected cells showed greater reduction of DENV production and cytokine/chemokine transcription. Similar results of this combined treatment were observed for infection with any one of the four DENV (DENV1, 2, 3, and 4) serotypes. These results indicate that combination of the antiviral agent and the anti-inflammatory compound offers a greater efficiency in reduction of DENV and cytokine/chemokine production, providing a new therapeutic approach for DENV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma
- Author
-
Junking, Mutita, Wongkham, Chaisiri, Sripa, Banchob, Sawanyawisuth, Kanlayanee, Araki, Norie, and Wongkham, Sopit
- Subjects
- *
BILIARY tract , *DIGESTIVE organs , *BILE , *INTRAHEPATIC bile ducts - Abstract
Abstract: Galectin-3, a β-galactoside-binding lectin, is a multifunctional protein implicated in a variety of biological functions, including tumour cell adhesion, proliferation, differentiation, cancer progression and metastasis. The present study was performed to clarify the impact of galectin-3 expression on patients with liver fluke-associated cholangiocarcinoma. Galectin-3 expression was examined immunohistochemically in 53 patients with intrahepatic cholangiocarcinoma, who had undergone surgery without pre-operative therapy. All bile duct epithelium expressed galectin-3 with different intensities, according to the different histological subtypes. The poorly-differentiated type expressed galectin-3 less intensely than the papillary, well- to moderately-differentiated types (P =0.012). We observed the association of low galectin-3 expression with lymphatic invasion (P =0.002). Suppression of galectin-3 expression in two human cholangiocarcinoma cell lines using siRNA targeted to galectin-3 significantly increased cell migration and invasion without alterations in cell proliferation. Regulation of galectin-3 expression may therefore be an alternative therapeutic approach to control metastasis of cholangiocarcinoma. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
- Author
-
Supimon, Kamonlapat, Sangsuwannukul, Thanich, Sujjitjoon, Jatuporn, Chieochansin, Thaweesak, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Subjects
- *
PROGRAMMED cell death 1 receptors , *CYTOTOXIC T cells , *T cells , *CHIMERIC antigen receptors , *IMMUNE checkpoint proteins , *PROGRAMMED death-ligand 1 , *CHOLANGIOCARCINOMA - Abstract
Cholangiocarcinoma (CCA) is a lethal bile-duct cancer that is difficult to treat by current standard procedures. This drawback has prompted us to develop adoptive T-cell therapy for CCA, which requires an appropriate target antigen for binding of chimeric antigen receptor (CAR) T cells. Mucin 1 (MUC1), an overexpressed protein in CCA cells, is a potential target antigen for the CAR T-cell development. However, MUC1 overexpression also is associated with the upregulation of programmed death-ligand 1 (PD-L1), an immune checkpoint protein that prohibits anti-tumor functions of T cells, probably causing poor overall survival of patients with CCA. To overcome this problem, we developed anti-MUC1-CAR T cells containing PD-1-CD28 switch receptor (SR), namely αM.CAR/SR T cells, to target MUC1 and switch on the inhibitory signal of PD-1/PD-L1 interaction to activate CD28 signaling. Our lentiviral construct contains the sequences that encode anti-MUC1-single chain variable fragment, CD137 and CD3ζ, linked with P2A, PD-1 and CD28. Initially, the upregulations of MUC1 and PD-L1 proteins were confirmed in CCA cell lines. αM.CAR and SR were co-expressed in 53.53 ± 13.89% of transduced T cells, mainly CD8+ T cells (85.7 ± 0.75%, P <0.0001) with the effector memory phenotype (59.22 ± 16.31%, P < 0.01). αM.CAR/SR T cells produced high levels of intracellular tumor necrosis factor-α and interferon-γ in response to the activation by CCA cells expressing MUC1, including KKU-055 (27.18 ± 4.38% and 27.33 ± 5.55%, respectively, P < 0.05) and KKU-213A (47.37 ± 12.67% and 54.55 ± 8.66%, respectively, P < 0.01). Remarkably, the cytotoxic function of αM.CAR/SR T cells against KKU-213A cells expressing PD-L1 was significantly enhanced compared with the αM.CAR T cells (70.69 ± 14.38% versus 47.15 ± 8.413%, respectively; P = 0.0301), correlated with increased granzyme B production (60.6 ± 9.89% versus 43.2 ± 8.95%, respectively; P = 0.0402). Moreover, the significantly enhanced disruption of KKU-213A spheroids by αM.CAR/SR T cells (P = 0.0027), compared with αM.CAR T cells, was also observed. Taken together, the cytotoxic function of αM.CAR/SR T cells was enhanced over the αM.CAR T cells, which are potential to be further tested for CCA treatment. Cholangiocarcinoma (CCA) is a bile duct cancer with high incidence and mortality lacking of effective treatments. The tissues of patients with CCA show high mucin-1 antigen and immune checkpoint ligand-1 (PD-L1) expression that affect antitumor functions of the immune cells. To overcome this challenge, we developed anti-mucin-1/CAR T cells expressing PD-1-CD28 switch receptor (αM.CAR/SR T cells) that can switch the inhibitory signal of PD-1/PD-L1 to activate the cells. The αM.CAR/SR T cells showed high proliferation, cytokine production, cytotoxicity and modest LAG-3, TIM-3 exhaustion markers. Thus, the αM.CAR/SR T cells are potential to be further developed as adoptive T-cell therapy for CCA. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
- Author
-
Suwanchiwasiri, Kwanpirom, Phanthaphol, Nattaporn, Somboonpatarakun, Chalermchai, Yuti, Pornpimon, Sujjitjoon, Jatuporn, Luangwattananun, Piriya, Maher, John, Yenchitsomanus, Pa‑thai, and Junking, Mutita
- Subjects
- *
T cells , *INTEGRINS , *ANTINEOPLASTIC agents , *CHOLANGIOCARCINOMA , *IMMUNOLOGIC memory - Abstract
Advanced cholangiocarcinoma (CCA) presents a clinical challenge due to limited treatment options, necessitating exploration of innovative therapeutic approaches. Bispecific T cell engager (BTE)-armed T cell therapy shows promise in hematological and solid malignancies, offering potential advantages in safety over continuous BTE infusion. In this context, we developed a novel BTE, targeting CD3 on T cells and integrin αvβ6, an antigen elevated in various epithelial malignancies, on cancer cells. The novel BTE was generated by fusing an integrin αvβ6-binding peptide (A20) to an anti-CD3 (OKT3) single-chain variable fragment (scFv) through a G 4 S peptide linker (A20/αCD3 BTE). T cells were then armed with A20/αCD3 BTE (A20/αCD3-armed T cells) and assessed for antitumor activity. Our results highlight the specific binding of A20/αCD3 BTE to CD3 on T cells and integrin αvβ6 on target cells, effectively redirecting T cells towards these targets. After co-culture, A20/αCD3-armed T cells exhibited significantly heightened cytotoxicity against integrin αvβ6-expressing target cells compared to unarmed T cells in both KKU-213A cells and A375.β6 cells. Moreover, in a five-day co-culture, A20/αCD3-armed T cells demonstrated superior cytotoxicity against KKU-213A spheroids compared to unarmed T cells. Importantly, A20/αCD3-armed T cells exhibited an increased proportion of the effector memory T cell (Tem) subset, upregulation of T cell activation markers, enhanced T cell proliferation, and increased cytolytic molecule/cytokine production, when compared to unarmed T cells in an integrin αvβ6-dependent manner. These findings support the potential of A20/αCD3-armed T cells as a novel therapeutic approach for integrin αvβ6-expressing cancers. [Display omitted] • A20/αCD3 BTE targets both CD3 on T cells and integrin αvβ6 on cancer cells. • A20/αCD3-armed T cells exhibit higher antitumor activity compared to unarmed T cells. • A20/αCD3 BTE enhances T cell activation, proliferation, and cytokine secretion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
- Author
-
Sangsuwannukul, Thanich, Supimon, Kamonlapat, Sujjitjoon, Jatuporn, Phanthaphol, Nattaporn, Chieochansin, Thaweesak, Poungvarin, Naravat, Wongkham, Sopit, Junking, Mutita, and Yenchitsomanus, Pa-thai
- Subjects
- *
CHIMERIC antigen receptors , *CD19 antigen , *LYSIS , *CHOLANGIOCARCINOMA , *CANCER stem cells ,BILIARY tract cancer - Abstract
• CD133 expression in patient tissues and cholangiocarcinoma (CCA) cells were shown. • Anti-CD133 CAR4 T cells containing CD28/CD137/CD27/CD3ς was successfully created. • The concept of using anti-CD133 CAR4 T cells against CD133+ CCA cells is proved. • Anti-CD133 CAR4 T cells is a potential cancer immunotherapy for CCA treatment. Current treatment of cholangiocarcinoma (CCA) – a lethal bile duct cancer – is ineffective because the disease is usually diagnosed at late and advanced stage. Thus, a novel therapeutic modality is urgently required. Fourth-generation chimeric antigen receptor (CAR4) T cells was created to target CD133, a well-known cancer stem cell marker, that is highly expressed and associates with cancer progression. The anti-CD133-CAR4 T cells showed high efficacy against CD133-expressing CCA cells. Tumour cell lysis occurred in a dose- and CD133 antigen-dependent manner, and significantly higher, up to 57.59% ± 9.62 at effector to target ratio of 5:1 in a CCA cell line – KKU-213A cells, compared to mock control (p = 0.008). Similarly, significant IFN-γ (p = 0.011) and TNF-α (p = 0.002) upregulation was observed upon tumour treatment. The effectiveness of our anti-CD133-CAR4 T cells will be beneficial not only for CD133-expressing CCA, but also for other CD133-expressing tumours. This study may guide future in vivo study and clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
- Author
-
Sawasdee, Nunghathai, Thepmalee, Chutamas, Sujjitjoon, Jatuporn, Yongpitakwattana, Petlada, Junking, Mutita, Poungvarin, Naravat, Yenchitsomanus, Pa-thai, and Panya, Aussara
- Subjects
- *
CYTOTOXIC T cells , *T cells , *CELL death , *DENDRITIC cells , *CANCER cells , *ANTIGEN presentation - Abstract
• Combination of gemcitabine and immunotherapy was tested in cholangiocarcinoma (CCA). • Cytotoxic T-lymphocyte (CTL) activated by self-differentiated dendritic cell (SD-DC). • Pretreatment of chemo-resistant CCA with gemcitabine enhanced CTL killing ability. • Gemcitabine sensitized CCA cells via upregulation of HLA class I and Fas receptor. • This study supported a combination of chemotherapy and CTLs for chemo-resistant CCA. Cholangiocarcinoma (CCA) can resist chemotherapy resulting in treatment failure. Gemcitabine, a chemotherapeutic drug, can sensitize cancer cells to become susceptible to cytotoxic T-lymphocytes (CTLs). We, therefore, hypothesized that a combination of gemcitabine and CTLs would be more effective for CCA treatment than individual therapy. To test this hypothesis, we conducted an in vitro study using gemcitabine combined with CTLs to treat gemcitabine-resistant CCA (KKU-213) cells. KKU-213 cells were pretreated with gemcitabine and tested for killing by CTLs activated by dendritic cells that were prepared by three different methods, including: (i) monocyte-derived dendritic cells pulsed with cancer cell lysate (Mo-DC + Lys), (ii) self-differentiated dendritic cells pulsed with cancer-cell lysate (SD-DC + Lys), and (iii) SD-DC presenting tumor-associated antigen PRKAR1A (SD-DC-PR). KKU-213 cells pretreated with gemcitabine were killed by CTLs activated by either SD-DC + Lys or SD-DC-PR more efficiently than those activated by Mo-DC + Lys. Furthermore, KKU-213 cells pretreated with a low dose (2 µM) of gemcitabine significantly enhanced the cytotoxic activity of CTLs activated by either SD-DC + Lys or SD-DC-PR at all evaluated effector (E) to target cell (T) ratios. At an E:T ratio of 5:1, KKU-213 cells pretreated with gemcitabine enhanced the cytotoxic activity of CLTs by approximately 2.5-fold (greater than 50% cell death) compared to untreated condition. The upregulation of HLA class I upon pretreatment of KKU-213 cells with gemcitabine may suggest a mechanism that leads to alteration of the antigen presentation process to promote CTL functions. These findings support the concept of combination therapy for overcoming chemo-resistant CCA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.